Key Highlights
- Dr. Kartik Krishnan appointed as CEO and Board Member of OncoNano, succeeding Martin Driscoll.
- Over two decades of experience in cancer care, with significant contributions to R&D and pharmacovigilance.
- Promotion of Dr. Melissa Paoloni to Executive Vice President and COO, bolstering OncoNano’s strategic and operational leadership.
Source: Business Wire
Notable Quotes
- “Kartik is a highly experienced executive and passionate physician-scientist who has been an essential force for OncoNano’s success in the last two years,” – Dr. Brett Giroir, Chairman of the Board of Directors at OncoNano
- “I joined OncoNano almost two years ago on the promise of a technology that could change how cancer is treated and today am even more enthusiastic about its prospects,” – Dr. Kartik Krishnan, CEO at OncoNano Medicine
SoHC's Take
OncoNano Medicine, Inc.’s recent announcement appointing Dr. Kartik Krishnan as the new Chief Executive Officer marks a pivotal moment in the company’s pursuit of pioneering cancer therapies. Dr. Krishnan’s impressive background and proven leadership within OncoNano, coupled with his prior experience at Arcus Biosciences, sets a promising course for the company’s innovative approach to cancer treatment. This leadership transition occurs alongside the promotion of Dr. Melissa Paoloni, emphasizing a strategic bolstering of the executive team aimed at accelerating development and bringing transformative medicines to patients. OncoNano’s commitment to leveraging its ON-BOARD™ platform and advancing key programs like ONM-501 and pegsitacianine reflects a robust strategy to meet high unmet medical needs in oncology. Dr. Krishnan’s vision for the company, rooted in his passion for transforming cancer care through technology, is poised to navigate OncoNano through its next phase of growth and development in the competitive landscape of cancer therapeutics.
